Tag: Cell Transplantation
BALDWIN PARK, Calif., Jan. 3, 2019 /PRNewswire/ — StemCyte is pleased to announce that the U.S. Food and Drug Administration (FDA), on December 14, 2018, approved its Phase II Investigational New Drug (IND) application for Allogeneic Human Leukocyte Antigen (HLA)-Matched Umbilical Cord Blood Mononuclear Stem Cells (UCBMNC) (MC001) for the treatment of spinal cord injury.
During the past 2 decades, cell-based therapies for SCI have been researched in several studies. Replacement of damaged neural tissues and re-establishing connections between the central and peripheral nervous system is vital for the treatment strategy for patients with SCI. Thus, the cells having a potential of self-renewal and differentiating into multiple cell types would be best suited for patients with SCI. Dr Geeta Shroff, director Nutech Mediworld, in a recent research has published report on how human embryonic stem cells (hESC’s) can treat spinal cord injuries (SCI). The findings are first of its kind as the cell line developed was free from animal products and chromosomally stable. The uniqueness about the cell line that makes it exclusive is that the process of cell line was derived from a single hESC which is already patented and published in her earlier reports.
You might feel a bit down if you watch the news. Who wouldn’t?
Angry people might be grabbing headlines and making you wonder about the future, but the antidote is all around you.
Talk to some of your neighbors. Chances are, no matter what they look like or where they’re originally from, you’ll find they’re actually pretty decent people — just like you.
The little improvements we all try to make may not register much, but the accumulation of them all eventually does.
The Miami Project, at the University of Miami Miller School of Medicine, today announced the publication of its first Food and Drug Administration (FDA) approved Phase I clinical trial involving Schwann cells used to repair the damaged spinal cord, in the February issue of the Journal of Neurotrauma. Schwann cells are essential for the repair of nerve damage, and long thought to be able to increase recovery after spinal cord injury. The trial, performed at University of Miami / Jackson Memorial Hospital in Miami, is the first in a series designed to evaluate the safety and feasibility of transplanting autologous human Schwann cells to treat individuals with spinal cord injuries.
Spinal cord injuries are mostly caused by trauma, often incurred in road traffic or sporting incidents, often with devastating and irreversible consequences, and unfortunately having a relatively high prevalence (250,000 patients in the USA; 80% of cases are male). One currently explored approach to restoring function after spinal cord injury is the transplantation of olfactory ensheathing cells (OECs) into the damaged area. The hope is that these will encourage the repair of damaged neurons, but does it work? And if so, how can it be optimized?
The path to recovery from spinal cord injury (SCI) is full of challenges.
If you’re interested in taking part in research to evaluate investigational therapies for SCI, you may be interested in a clinical research study called Pathway that is evaluating the potential of neural stem cells to treat cervical spinal cord injury (cSCI).
What is the Pathway study?
The purpose of the Pathway Study is to evaluate the safety and potential benefit of neural stem cell transplantation for people with cSCI. If you are eligible for the study and if you choose to participate, your participation will last approximately 12 months.
The spinal cord is often called as a delicate tissue, which is secured inside very hard vertebrae of spinal column. The spinal cord and brain is seen forming the central nervous system of our body. The spinal cord is basically made up of millions of nerve cells, which carry a number of signals to our brain and out over the other parts of human body. Unfortunately with issues like injuries with accident and with age or other ailments the spinal cord can end up getting injured. There are certain spinal cord injuries, which can be fixed with the help of treatment options like cell transplantation. Now, let us dig in deep into this treatment option in the following paragraphs:
A paraplegic undergoes pioneering surgery.
When a spinal cord is damaged, location is destiny: the higher the injury, the more severe the effects. The spine has thirty-three vertebrae, which are divided into five regions—the coccygeal, the sacral, the lumbar, the thoracic, and the cervical. The nerve-rich cord traverses nearly the entire length of the spine. The nerves at the bottom of the cord are well buried, and sometimes you can walk away from damage to these areas. In between are insults to the long middle region of the spine, which begins at the shoulders and ends at the midriff.
Patients treated for spinal cord injury (SCI) using olfactory mucosa lamina propria (OLP) transplants demonstrated modest improvements, according to research published in Cell Transplantation.
A global team of researchers aimed to determine whether OLP transplants promote regeneration and functional recovery in chronic human SCI by randomizing 12 subjects to OLP transplants (8 patients) or control sham surgery (4 patients). The subjects were examined using magnetic resonance imaging (MRI), electromyography (EMG), urodynamic study (UDS), American Spinal Injury Association impairment scale (AIS), and other functional assessments. The researchers commented that high levels of nerve growth factor and neurotrpohic receptor expression are typically demonstrated by autologous olfactory ensheathing cells (OECs).
- Four biotech companies are pursuing the treatment of spinal cord injury with the use of stem cell transplantation.
- Each company demonstrated efficacy in pre-clinical studies.
- The race is in the early stages but InVivo Therapeutics is clearly leading the pack based on its strategic approach to accelerated HDE approval and initial trial results.